Artvin Merkez

Researchers are evaluating the efficacy and safety of rilvegostomig compared to pembrolizumab monotherapy as the first-line treatment for patients with metastatic non-small cell lung cancer mNSCLC whose tumors express high levels of PD-L1. This Phase III, randomized, double-blind, multicenter global study focuses on patients with mNSCLC without certain genetic mutations who are suitable for this treatment approach. Participants are randomly assigned to receive either rilvegostomig or pembrolizumab intravenously on Day 1 of each 21-day cycle. The study compares these two drugs over repeated treatment cycles as first-line therapy. Both treatments are biological agents given by infusion, and the study is designed to monitor their effects over up to approximately five years. During the trial, participants will undergo regular assessments including physical exams, imaging scans such as CT or MRI to measure tumor lesions, and laboratory tests to evaluate organ function. Researchers will closely monitor overall survival, progression-free survival, treatment response, duration of response, and patient-reported outcomes on physical functioning and quality of life. Safety and immunogenicity of rilvegostomig will also be evaluated. Participants are followed and assessed for up to five years to gather comprehensive data on treatment effects and long-term outcomes.

Researchers are evaluating the efficacy, safety, and tolerability of elecoglipron compared with placebo in adults who have type 2 diabetes mellitus T2DM with impaired kidney function. Participants are also on dapagliflozin 10 mg as part of their guideline-directed medical therapy for chronic kidney disease CKD, along with other glucose-lowering medications. This Phase III study aims to understand how elecoglipron performs in this specific group of patients. Participants will be randomly assigned to one of three groups elecoglipron at dose level 1, elecoglipron at dose level 2, or placebo. All treatments are given orally once daily alongside background dapagliflozin 10 mg. The study uses a parallel design and includes a 40-week treatment period during which participants take their assigned medication. During the study, participants will have their blood sugar control measured through Hemoglobin A1c HbA1c levels from baseline to Week 40, which is the primary outcome. Additional assessments include body weight changes, blood pressure, fasting plasma glucose, and time to needing additional diabetes medication. Safety and tolerability will be monitored throughout the study, which lasts up to 40 weeks for each participant.

Researchers are conducting a combined Phase 2b and Phase 3 clinical trial to study CSL300 Clazakizumab in adults with end stage kidney disease ESKD who are undergoing maintenance dialysis. The study aims to find the right dose of CSL300 and then evaluate its effect on cardiovascular outcomes and safety in people with systemic inflammation and either atherosclerotic cardiovascular disease ASCVD or diabetes. This is a randomized, double-blind, placebo-controlled study involving multiple centers. Participants will receive intravenous IV administration of either CSL300 or a placebo. The Phase 2b part focuses on determining the appropriate dose of CSL300 compared to placebo over about 12 weeks, while the Phase 3 part examines CSL300s effect on cardiovascular events over approximately five years. The study includes different dosing groups in Phase 2b and a larger comparison of CSL300 versus placebo in Phase 3. During the study, participants will be monitored regularly with blood tests that measure inflammation markers such as high-sensitivity C-reactive protein hs-CRP, cardiovascular events, and safety outcomes. Researchers will track changes in various blood components and adverse events up to 32 weeks in Phase 2b and follow cardiovascular outcomes for up to five years in Phase 3. The total participation lasts through these periods with scheduled assessments to evaluate treatment effects and safety.

This research aims to evaluate how digital parenting education affects mothers knowledge and attitudes about their childrens use of technology and their own social media addiction levels. Conducted as a randomized controlled trial, the study focuses on mothers of healthy preschool children aged 3 to 6 years registered at a family health center. The study seeks to assess the impact of educational sessions on digital parenting awareness and social media habits among these mothers. Participants are randomly assigned to either an experimental group receiving digital parenting education or a control group without intervention during the main study phase. The education consists of eight face-to-face sessions, each lasting 20 minutes, delivered twice a week. The training covers topics such as the role of digital parenting, effects of technology on parent-child relationships and child behavior, appropriate social media use, and managing risks and opportunities of digital tools. The control group completes pre- and post-test assessments and is offered a brief educational session and brochure after the study. Mothers complete questionnaires measuring their knowledge and attitudes about technology use and social media addiction before and after the intervention. Data collection includes sociodemographic information and specific scales on parental knowledge, attitudes, and social media addiction. The study uses statistical methods to compare changes between groups over 12 weeks. Participant involvement includes consent, pre-test, education sessions for the experimental group, post-test, and follow-up assessments. The total study duration spans from March to December 2025.

Breast cancer patients undergoing chemotherapy often face psychological distress, anxiety, and reduced comfort during treatment. This trial evaluates whether mandala coloring during outpatient chemotherapy sessions can help reduce these negative feelings and improve comfort. The study is a randomized controlled experimental trial designed to provide evidence about a simple, low-cost supportive method for enhancing well-being in breast cancer patients receiving chemotherapy. Participants are randomly assigned to either an intervention group or a control group. Those in the intervention group will color mandala patterns for 30 minutes during their chemotherapy session using provided coloring books and pencils, while continuing to receive routine medical care. The control group will receive routine outpatient chemotherapy care without any additional activity. Participants will have their psychological distress, anxiety, and comfort levels measured both before and immediately after the chemotherapy session using validated scales. Researchers will compare these measurements between groups to assess the effect of mandala coloring. The study is expected to provide valuable insights into improving the psychological well-being of breast cancer patients during outpatient chemotherapy sessions.

Researchers are evaluating the efficacy and safety of Imeroprubart in adults with active Chronic Inflammatory Demyelinating Polyneuropathy CIDP, a condition affecting the peripheral nerves. This Phase 2b, multi-center, randomized, double-blind, placebo-controlled study aims to understand how well Imeroprubart works compared to placebo in treating CIDP. The study is sponsored by Immunovant Sciences GmbH and focuses specifically on adults meeting diagnostic criteria for typical or variant forms of CIDP. Participants will receive either Imeroprubart or a matching placebo by subcutaneous injection once weekly. The treatment period includes an initial 24-week phase Period 1 with Imeroprubart or placebo, followed by an extension to 52 weeks Period 2 for continued evaluation. Imeroprubart dosing is given once weekly via subcutaneous injection. Placebo is provided similarly during the first 24 weeks. During the study, participants will be monitored through clinical assessments including relapse status by Week 24, as well as measurements of disability, grip strength, muscle strength, and symptom scores. Electrodiagnostic tests support diagnosis at baseline. Safety and efficacy will be closely observed during treatment, with follow-up visits scheduled to assess outcomes. The total participation duration covers at least 24 weeks for the primary outcome assessment, with ongoing monitoring as defined by the study protocol.

This research aims to evaluate the effects of Laughter Yoga on sleep quality, vitality, active aging, and quality of life in individuals aged 60 and over. The study will be conducted as a randomized controlled trial involving elderly participants registered at a family health center. It addresses the potential benefits of laughter yoga, a low-cost and practical intervention, based on prior evidence showing positive effects on physiological and psychosocial health. Participants will be randomly assigned to either an experimental group or a control group. The experimental group will attend 12 Laughter Yoga sessions lasting 40 minutes each, held twice weekly over six weeks. These sessions include deep breathing, clapping and warm-up exercises, childlike play, and laughter exercises, all led by a certified instructor. The control group will receive no intervention during this period. Both groups will undergo assessments before and after the six-week period using tools such as the Mini-Mental State Examination, Active Aging Scale, Pittsburgh Sleep Quality Index, Subjective Vitality Scale, and Quality of Life Scale for the Elderly. Attendance will be monitored through phone contacts, and participants will continue their regular medications. The study measures changes in sleep quality, vitality, active aging, and overall quality of life to assess the impact of the laughter yoga intervention.

Researchers are evaluating whether using a stress ball during chemotherapy can help reduce anxiety, fear, and changes in vital signs in patients with gastrointestinal system cancers. This randomized controlled study includes adult patients undergoing chemotherapy, who often experience emotional and physiological stress during treatment. The study aims to provide evidence on whether a simple, non-drug method like stress ball squeezing can improve emotional well-being and physical stability during chemotherapy. Participants will be randomly assigned to one of two groups the stress ball intervention group or the routine care group. Those in the stress ball group will squeeze a medium-firm stress ball for 15 minutes starting at the beginning of their chemotherapy session, guided to inhale while squeezing and exhale while releasing the ball. The control group will receive routine chemotherapy care without additional interventions. Participants will have their anxiety and fear levels measured before and immediately after chemotherapy using validated tools. Vital signs such as blood pressure, heart rate, respiratory rate, body temperature, and oxygen saturation will also be recorded at these times. The study will compare these measures between both groups to assess the impact of stress ball use during chemotherapy. The total duration of participation covers the chemotherapy session with these before-and-after assessments.

Researchers are investigating whether tightly controlling blood pressure during major non-cardiac surgery can reduce serious complications related to poor blood flow, such as heart injury, stroke, kidney damage, infections, sepsis, and death within 30 days after surgery. This international randomized trial compares two approaches to managing blood pressure during surgery to see which might better prevent these serious events. The study involves adults aged 45 and older undergoing major surgeries expected to last at least two hours and requiring general or neuraxial anesthesia. Participants are randomly assigned to one of two groups tight blood pressure management or routine blood pressure management. In the tight management group, medications norepinephrine or phenylephrine are infused to keep the mean arterial pressure MAP at or above 85 mmHg during surgery, and certain blood pressure medications are withheld on the morning of surgery. In the routine management group, blood pressure is managed as usual, with blood pressure medications allowed if the anesthesiologist agrees. Other aspects of anesthesia and postoperative care are handled per standard procedures and clinician judgment in both groups. During the study, participants will be monitored closely through blood pressure measurements and clinical assessments. Researchers will track the occurrence of major perfusion-related complications in the first 30 days after surgery as the primary outcome. They will also assess postoperative delirium during the first four days after surgery. The study includes detailed anesthesia management and hospitalization, aiming to capture important health outcomes while ensuring patient safety. Participation lasts through the initial postoperative period with ongoing monitoring as needed.